Relevant bibliographies by topics / HIV infections – Treatment – Asia

Academic literature on the topic 'HIV infections – Treatment – Asia'

Author: Grafiati
Published: 4 June 2021
Last updated: 19 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'HIV infections – Treatment – Asia.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "HIV infections – Treatment – Asia"

1

Phuphuakrat, Angsana, Sasisopin Kiertiburanakul, and Somnuek Sungkanuparph. "Current status of HIV treatment in Asia and the Pacific region." Sexual Health 11, no. 2 (2014): 119. http://dx.doi.org/10.1071/sh13045.

Full text
Abstract:
Asia and the Pacific represent a diverse group of nations facing HIV epidemic profiles of differing severity. Compared to other parts of the world, the burden of HIV disease is high in this region because of its large populations. At the end of 2011, 5 million people were living with HIV in Asia and the Pacific. This accounted for 15% of people living with HIV worldwide. The prevalence of people living with HIV, as well as access to HIV treatment and care, varies widely between countries. Differences between high-income economies and the rest of the continent are remarkable. Many high-income countries provide antiretroviral therapy (ART) to their citizens. Middle- and low-income countries have rapid ART scale-up and are dependent on international funding. This may compromise the sustainability of ART availability. In addition, lack of access to second- and third-line therapy remains a problem in many countries. The global goal of achieving universal access to ART by 2015 requires mainly low- and middle-income countries to be targeted. Regional policy should be developed in order to identify new infections in key populations, to start earlier treatment, to retain patients in care and to maintain funding.
APA, Harvard, Vancouver, ISO, and other styles
2

Cohen, Myron S., Theresa Gamble, and Marybeth McCauley. "Prevention of HIV Transmission and the HPTN 052 Study." Annual Review of Medicine 71, no. 1 (January 27, 2020): 347–60. http://dx.doi.org/10.1146/annurev-med-110918-034551.

Full text
Abstract:
The HIV Prevention Trials Network 052 study (HPTN 052) was a clinical trial designed to determine whether early treatment for HIV infection prevented transmission of the virus in couples where one partner was infected with HIV and the other was not, referred to as HIV serodiscordant or serodifferent couples. The study enrolled 1,763 couples at 13 sites in 9 countries in Asia, Africa, and the Americas. HPTN 052 demonstrated a minimum of 96% reduction of HIV in heterosexual couples ascribed to antiretroviral treatment; early treatment of HIV significantly reduced other infections in the HIV-infected subjects. This study, in conjunction with similar research, led to significant changes in international HIV treatment guidelines and the concept of treatment as prevention (TasP). This article provides the scientific background and history of how HPTN 052 came into being, the challenges it faced, and the ultimate impact it had on the fields of HIV treatment and prevention.
APA, Harvard, Vancouver, ISO, and other styles
3

Naggie, Susanna, Daniel S. Fierer, Michael D. Hughes, Arthur Y. Kim, Annie Luetkemeyer, Vincent Vu, Jhoanna Roa, et al. "Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals." Clinical Infectious Diseases 69, no. 3 (March 28, 2019): 514–22. http://dx.doi.org/10.1093/cid/ciy913.

Full text
Abstract:
Abstract Background Current guidelines for the management of hepatitis C virus (HCV) infections provide varying recommendations for the optimal treatment of acute HCV infections. There are limited data from small cohort studies to provide guidance on the best approach to treatment of this important patient population. Methods Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals is an open-label, 2-cohort, Phase 1 clinical trial in which the second cohort assessed the safety and efficacy of 8 weeks of ledipasvir/sofosbuvir for the treatment of acute HCV infections in participants with chronic human immunodeficiency virus (HIV)-1 infections. This final analysis of the second cohort had a planned accrual of 27 participants, based on non-inferiority criteria, compared to the study-defined, historical, sustained virologic response (SVR) of 60% with pegylated-interferon/ribavirin. Results We enrolled 27 men (9 Hispanic; 11 White, non-Hispanic; 5 Black, non-Hispanic; 2 Asian or Pacific Islander; median age 46 years). Most (96%) had HCV genotype-1 infection and 59% had the favorable interleukin 28B CC genotype. The median baseline HCV RNA load was 6.17 log10 IU/mL (interquartile range 4.51 – 6.55). All participants (100%) achieved the primary outcome of a sustained virologic response 12 weeks after the date of the last dose of study treatment (90% confidence interval 90–100%), achieving non-inferiority versus the 60% historic benchmark. No treatment discontinuations occurred. Conclusions This multicenter clinical trial, investigating 8 weeks of ledipasvir/sofosbuvir for acute HCV infections in men with HIV infections, reports a 100% SVR. This study provides the rationale for larger studies of shortened courses of direct-acting antiviral therapies in persons with HIV infections, including those with high baseline HCV RNA loads. Clinical Trials Registration NCT02128217.
APA, Harvard, Vancouver, ISO, and other styles
4

Cassell, Michael M., Timothy H. Holtz, Mitchell I. Wolfe, Michael Hahn, and Dimitri Prybylski. "'Getting to zero' in Asia and the Pacific through more strategic use of antiretrovirals for HIV prevention." Sexual Health 11, no. 2 (2014): 107. http://dx.doi.org/10.1071/sh13116.

Full text
Abstract:
Encouraged by experimental trials demonstrating the efficacy of antiretrovirals (ARVs) in preventing HIV infection, countries across the Asia-Pacific region have committed to the achievement of ambitious targets tantamount to ending AIDS. The available data suggest that some countries still can make progress through targeted condom promotion and the expansion of harm-reduction interventions, but that none may realise its vision of ‘zero new HIV infections’ without more strategic use of ARVs as part of a combination of HIV prevention efforts targeting key populations. Low rates of HIV testing among men who have sex with men, people who inject drugs, sex workers and other key populations evidence low treatment coverage where treatment could have the greatest impact on curbing local epidemics. Studies have demonstrated the promise of adding ARV treatment and pre-exposure prophylaxis to the existing HIV prevention toolkit, but achieving population-level impact will require service-delivery approaches that overcome traditional prevention, care and treatment program distinctions. Priorities include: (1) innovative strategies to reach, test, treat and retain in services the individuals most likely to acquire or transmit HIV; (2) task shifting and enhanced partnerships between the public sector and civil society; (3) improved ‘cascade’ data systems to assess and promote service uptake and retention; and (4) policy and financing reform to enhance HIV testing and treatment access among key populations.
APA, Harvard, Vancouver, ISO, and other styles
5

Ohata, Pirapon June, Stephen J. Kerr, Anchalee Avihingsanon, Reshmie Ramautarsing, Sivaporn Gatechompol, Thornthun Ueaphongsukkit, Nittaya Phanuphak, et al. "Conference proceedings from the 22nd Bangkok International Symposium on HIV Medicine." Future Virology 15, no. 4 (April 2020): 211–14. http://dx.doi.org/10.2217/fvl-2020-0009.

Full text
Abstract:
The Bangkok International Symposium on HIV Medicine is one of the longest running and largest international conferences in the Asia–Pacific, providing healthcare workers with the most up-to-date information pertaining to HIV and coinfections. In the third week of January 2020, 500 HIV researchers and service providers from over 21 countries worldwide gathered in Bangkok to share data and experiences in the treatment and prevention of HIV, TB and sexually transmitted infections. Highlights of the 2020 symposium included a roundtable discussion of pre-exposure prophylaxis, a 1-day forum on TB, the potential for a HBV cure and, for the first time, oral presentations from four young investigators from the region.
APA, Harvard, Vancouver, ISO, and other styles
6

Kusumaadhi, Zaki Mita, Nur Farhanah, and Muchlis Achsan Udji Sofro. "Risk Factors for Mortality among HIV/AIDS Patients." Diponegoro International Medical Journal 2, no. 1 (March 10, 2021): 20–19. http://dx.doi.org/10.14710/dimj.v2i1.9667.

Full text
Abstract:
Background: Morbidity and mortality of HIV/AIDS infections is still high and as a global health problem particularly in Low-Middle Income Countries (LMICs). Indonesia ranks third in Asia Pacific in increasing HIV infection. A Study on risk factors for mortality in HIV/AIDS patients in Dr. Kariadi General Hospital has never been conducted. This study analyzed the risk factors for mortality among HIV/AIDS patients.Methods: Case control study, data from medical records of inpatients and outpatients in Dr. Kariadi General Hospital from January 2015 to December 2017.Results: Study subject: Two hundred and ten HIV/AIDS patients, were included; 105 (56.75%) as cases and 105 (9.65%) control patients. The significant risk factors for mortality were as follow: male sex (p = 0.030); age ≥ 45 years (p = 0.035); non compliance to treatment (p = 0,000); WHO clinical stage III and IV (p = 0,000); co-infection of pulmonary tuberculosis (p = 0,000); CD4 cell count < 200 cells/mm3 (p = 0,000); eGFR < 60 mL/minute/1.72 m2 (p = 0.001) and Haemoglobin level < 10 g/dL (p = 0.008). The non-significant risk factors for mortality were as follow: level of education (p = 0.650); Hepatitis B co-infection (p = 0.153) and Hepatitis C co-infection (p = 0.506). The most important risk factors for mortality in this study in were non compliance to treatment (p = 0.003; OR = 3.285) and CD4 count < 200 cells/mm3 (p = 0.014; OR = 5.480).Conclusion: In this study, the risk factors for mortality in HIV/AIDS patients were male sex; age ≥ 45 years; non compliance to treatment; WHO clinical stage III and IV; co-infection of pulmonary tuberculosis, CD4 count < 200 cells/mm3; eGFR < 60 mL/minute/1.72 m2 and Hb level < 10 g/dL. The most important risk factors for mortality were non compliance to treatment and CD4 count < 200 cells / mm3.
APA, Harvard, Vancouver, ISO, and other styles
7

Aung, Myo Nyein, Saiyud Moolphate, Damodar Paudel, Mangalasiri Jayathunge PH, Duangjai Duangrithi, Kinley Wangdi, Thin Nyein Nyein Aung, Thaworn Lorga, and Kazue Higuchi. "Global evidence directing regional preventive strategies in Southeast Asia for fighting TB/HIV." Journal of Infection in Developing Countries 7, no. 03 (March 14, 2013): 191–202. http://dx.doi.org/10.3855/jidc.2903.

Full text
Abstract:
Tuberculosis (TB) and human immunodeficiency virus (HIV) co-epidemics form a huge burden of disease in the Southeast Asia region. Five out of eleven nations in this region are high TB/HIV burden countries: Myanmar, Thailand, India, Indonesia and Nepal. The trends of TB incidence in these countries have been rising in recent years, in contrast to a falling global trend. Experts in the field of TB control and health service providers have been perplexed by the association of TB and HIV infections which causes a mosaic clinical presentation, a unique course with poor treatment outcomes including death. We conducted a review of contemporary evidence relating to TB/HIV control with the aims of assisting integrated health system responses in Southeast Asia and demystifying current evidence to facilitate translating it into practice.
APA, Harvard, Vancouver, ISO, and other styles
8

Palumbo, Emilio, Gaetano Scotto, Giuseppina Faleo, Donatella Concetta Cibelli, Annalisa Saracino, and Gioacchino Angarano. "Prevalence of HBV-genotypes in immigrants affected by HBV-related chronic active hepatitis." Arquivos de Gastroenterologia 44, no. 1 (March 2007): 54–57. http://dx.doi.org/10.1590/s0004-28032007000100012.

Full text
Abstract:
BACKGROUND: The genetic heterogeneity of the HBV genome has been established and eight genotypes can be classified according to the criterion of >8% differences in the complete nucleotide sequence of the viral genome. AIMS: To evaluate the prevalence of HBV-infection in a population of immigrants and to determine in patients with detectable serum HBV-DNA the HBV-genotypes. METHODS: Between January 2005 and December 2005 a total of 556 immigrants were tested for HBsAg. In HBsAg positive patients the biochemical and virological activity of infection and the possible presence of co-infections (HCV, HDV, HIV) were evaluated. In patients with detectable serum HBV DNA, the HBV-genotype was determined by INNOLiPA. RESULTS: Among the 556 subjects tested, 60 (10.7%) resulted HBsAg positive. All were men, and 42 (70%) come from Africa, 10 (16.6%) from Asia and 9 (14.4%) from East-Europe. 28/60 (46.6%) patients presented normal ALT levels (<40 IU/L) and undetectable serum HBV DNA (<100 copies/mL in real-time PCR), while 32 (53.4%) patients had ALT levels above laboratory normal values and detectable serum HBV DNA. Genotype distribution was as follow: genotype E, 16 (50%), genotype D, 9 (28.1%), genotype A, 7 (21.9%). CONCLUSION: Our study evidences a moderate prevalence of HBV-infection in immigrants, particularly in sub-Saharan African people, and the potentiality of migratory flow in the introduction of genotype non-D hepatitis B virus, potentially characterized by a different natural history and, possibly, a different response to antiviral treatment.
APA, Harvard, Vancouver, ISO, and other styles
9

Amerzhanov, Daulet, Indira Suleimenova, Salima Davlidova, Zhamilya Nugmanova, and Syed Ali. "HBV Prevention and Treatment in Countries of Central Asia and the Caucasus." Viruses 12, no. 10 (September 30, 2020): 1112. http://dx.doi.org/10.3390/v12101112.

Full text
Abstract:
The countries of Central Asia and the Caucasus are linked by travel and trade, which is promoted by visa-free mobility across borders. Unfortunately, this migrant mobility has given rise to the transmission of various infections within this region. Overlaps in culture, tradition, and behavior among these countries provide opportunities to share experiences that have proven effective in controlling transmission. Here we present a review of hepatitis B virus (HBV) prevalence, prevention and treatment across Central Asia and the Caucasus. Overall, owing to effective measures, while HBV prevalence has been steadily declining in the region, certain gaps still exist regarding the generation and availability of HBV infection data.
APA, Harvard, Vancouver, ISO, and other styles
10

Maek-a-Nantawat, Wirach, Anchalee Avihingsanon, and Pirapon June Ohata. "Challenges in Providing Treatment and Care for Viral Hepatitis among Individuals Co-Infected with HIV in Resource-Limited Settings." AIDS Research and Treatment 2012 (2012): 1–10. http://dx.doi.org/10.1155/2012/948059.

Full text
Abstract:
Hepatitis B and C infections are prevalent among HIV-infected individuals with different epidemiologic profiles, modes of transmission, natural histories, and treatments. Southeast Asian countries are classified as “highly prevalent zones,” with a rate of hepatitis B and C coinfection in people living with HIV/AIDS of approximately 3.2–11%. Majority of hepatitis B coinfection is of genotype C. Most of the patients infected with hepatitis C in Thailand have genotype 3 which is significantly related to intravenous drug use whereas, in Vietnam, it is genotype 6. The options for antiretroviral drugs are limited and rely on global funds and research facilities. Only HBV treatment is available for free through the national health scheme. Screening tests for HBV and HCV prior to commencing antiretroviral treatment are low. Insufficient concern on hepatitis-virus-related liver malignancy and long-term hepatic morbidities is noted. Cost-effective HCV treatment can be incorporated into the national health program for those who need it by utilizing data obtained from clinical research studies. For example, patients infected with HCV genotype 2/3 with a certain IL-28B polymorphism can be treated with a shorter course of interferon and ribavirin which can also help reduce costs.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "HIV infections – Treatment – Asia"

1

Wong, Mei-wan Farah, and 黃美雲. "Financial burden for HIV/AIDS patients to access antiretroviral therapy in Asian developing countries." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hdl.handle.net/10722/193826.

Full text
Abstract:
Background: Since the beginning of 21st century, several Asian countries started implementing their national free antiretroviral therapy (ART) programs to tackle one of the most striking public health issues in Asia – HIV/AIDS. Despite the efforts being made, the treatment coverage remains as low as 44% in 2010. Previous studies have identified financial constraint is a major barrier in accessing ART and an important reason of poor ART adherence in Asia. The purpose of this literature review is to explore the extent of financial burden experienced by people living with HIV (PLHIV) where free ART policy is implemented, and to provide valuable information for policy-making in reducing financial barriers and improve uptake of ART. Methods: Literature search was performed by entering keywords in PubMed and Medline. Articles were screened and selected for in-depth review according to the inclusion and exclusion criteria. A process on data synthesis was performed on the final eligible papers. Results: Five studies from four Asian countries describing the out-of-pocket health expenditure incurred by PLHIV during the delivery of ART were included in this review. Findings: Out of all direct medical costs, the cost of drug was most important in contributing to the total costs for patients without health insurance, while the cost of transportation was more important for patients covered by health insurance. Direct medical costs increased with advancing stage of disease. Rural patients would have spent up to 1,173% of their monthly income per capita, or more than 100% of their total household expenditure even when ART was provided free-of-charge. Patients have also highlighted free ARV drugs were sometimes not available in the health facility and they had to turn to the private market. Hence, the extent of financial burden in this review might be underestimated. Conclusion: Based on the data available, we concluded that increased accessibility of free ART should be accompanied with sustained ARV drugs supply and increased financial support for PLHIV.
published_or_final_version
Community Medicine
Master
Master of Public Health
APA, Harvard, Vancouver, ISO, and other styles
2

Srasuebkul, Preeyaporn Public Health &amp Community Medicine Faculty of Medicine UNSW. "Evaluating monitoring strategies, short-term disease progression and rate of treatment change in HIV-infected patients commencing antiretroviral therapy in the Asia-Pacific region." Publisher:University of New South Wales. Public Health & Community Medicine, 2008. http://handle.unsw.edu.au/1959.4/41673.

Full text
Abstract:
This thesis assesses factors associated with a number of short and long-term outcomes in HIV-infected patients receiving antiretroviral treatment in Asia. Analyses in this thesis were based on two cohorts of HIV-infected patients; The Treat Asia HIV Observational Database (TAHOD), a multi-centre prospective observational cohort from countries in Asia-Pacific region, and the HIV Netherlands Australia Thailand (HIV-NAT) collaboration cohort, a cohort of patients treated with antiretroviral treatments at HIV-NAT in Bangkok, Thailand. We examined factors associated with time to immunological failure endpoints, such as CD4≤ 200 cells/??L, CD4≤ 100 cells/ ??L, and CD4 return to baseline, and with the virological failure endpoint, detectable viral load defined as a value greater than 500 copies/mL. Multivariate Cox proportional hazard models were used. Results showed that CD4 count at baseline and changes in CD4 strongly predicted immunological failure. For virological failure, detectable viral load at baseline was the strongest predictor. As a step to developing simplified monitoring strategies, in which patients with a low risk of failure could have their monitoring CD4 count and viral load tests deferred, we developed predictive models for each immunological and virological failure endpoint. Models were developed on the HIV-NAT cohort, and validated on the independent TAHOD cohort. For predictive models, the complementary log-log transformation for each endpoint was fitted appropriate to the interval censored nature of the data. To assess goodness-of-fit, cut-offs were defined for the predicted risks that separated patients from low risk to high risk. Overall, the observed versus expected failures from HIV-NAT data agreed quite well across all endpoints, probably reflecting that the HIV-NAT database was the data we built the models upon. Not only did these models fit the HIV-NAT database well, they also discriminated patients from low to high risk groups. When we validated models with TAHOD data, the observed and expected failures agreed well only in the model for CD4 count return to baseline. For most of the endpoints, the predictive models overestimated the number of failures, with predicted values larger than observed. However, the proportions of failures were lowest in the low risk group and highest in the high risk group, indicating that our models did discriminate between patients at high and low risk, and that the predictive models might still be of use for the purpose of simplified monitoring strategies. With CD4 count and viral load monitoring tests now comprising a large component of the cost of HIV treatment in resource limited settings, we developed and assessed a simplified monitoring strategy that aimed to reduce the numbers of monitoring tests performed. The predictive models developed earlier were used to calculate the probabilities of failure in TAHOD patients. We assumed that patients would have their CD4 and viral load assessments annually, at baseline and at one year, predicted risk of failure at ensuing clinical visits, week 12, 24 and 36. For patients at low predicted risk of failure at ensuing clinical visits, we assessed the effect of deferring monitoring tests, both in terms of blood tests avoided, and in terms of delaying detection of failure in some patients. A number of levels for the predicted risk of failure that lead to deferral of testing were evaluated. The results suggested that predicted probabilities of failure of 10% - 20% gave the best results across all failure endpoints. These cut-offs could save a median of 598 (51.6%) (range 37 (2.6%)_-1,218 (81.9%) ) blood tests over the first year of treatment, but would fail to detect 29 (18%) (range 10 (7.4%) - 128 (39.3%) ) failures. The median time from failure to detection in those patients who did fail and had deferred monitoring tests was 28 weeks. Rates of antiretroviral treatment change in TAHOD were examined. We identified patterns and factors associated with the rate of treatment change. Median time to the first treatment change was 3.2 years. Factors predicting rate of treatment change in TAHOD were treatment combination, being on second or third combination, number of drugs available in each site and being an injecting drug user. The overall rate of treatment change in TAHOD was 29 per 1OO-person-year. Around 30% of patients stopped their treatment due to adverse events. These rates of treatment change are lower than have been seen in patients in western countries. This may be due to patients in developing countries having access to fewer antiretroviral drugs than patients in developed countries.
APA, Harvard, Vancouver, ISO, and other styles
3

Tang, Chui-ying, and 鄧翠瑩. "Migration and the risk of HIV infection: a review in Asia." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B4842559X.

Full text
Abstract:
Asia has populated with the second largest number of people living with HIV/AIDS. Under the advancement of transportation, the open up of borders between cities and countries, and the process of globalisation, people move from their place of origin to other places for better living conditions and employment opportunities. Mobile people and migrants are identified as the high risk population of HIV infection. Poverty, discrimination, limited access to healthcare and social services, separation with supports and families, being alienated in resident communities, and gender inequalities are the unfavourable conditions which make the migrant population vulnerable to HIV infection. Existing literatures have investigated and examined the potential risk factors among the mobile population. Inconsistencies were found among research but high risk sexual behaviours and poor knowledge and attitude were observed and reviewed within the migrants. However, literatures which compared the people who migrated with other local people in the same population were not yet reviewed systemically. Therefore, this paper aimed to review the articles which compare the migrant group and the non-migrant group in Asian population to identify the association between migration and the risks of HIV infection. A literature search of five databases (PubMed, Medline, Cochrane, CNKI, Wanfang Med Online) was performed and nine articles were eventually selected for review. The migration status of literature was studied as explanatory variable and compared across studies. Outcome variables of interest were grouped into four categories as: demographic characteristics, sexual practices, awareness towards HIV/AIDS, and disease prevalence. To conclude, compared to people who did not migrate, migrants in Asia were more tend to be less educated, have multiple sex partners, engage in high risk sexual intercourse and commercial sex, but their overall condom usage were lower. Also, they had higher risk of sexually transmitted infections and poorer knowledge in HIV/AIDS.
published_or_final_version
Public Health
Master
Master of Public Health
APA, Harvard, Vancouver, ISO, and other styles
4

Weinberger, Beverley Slome Kloss Jacqueline D. "Posttraumatic stress in adolescents with HIV and its relationship with treatment adherence : the role of health beliefs /." Philadelphia, Pa. : Drexel University, 2010. http://hdl.handle.net/1860/3221.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Petoumenos, Kathy Public Health &amp Community Medicine Faculty of Medicine UNSW. "Treatment experience and HIV disease progression: findings from the Australian HIV observational database." Awarded by:University of New South Wales. School of Public Health and Community Medicine, 2006. http://handle.unsw.edu.au/1959.4/24937.

Full text
Abstract:
The Australian HIV Observational Database (AHOD) is a collaboration of hospitals, sexual health clinics and specialist general practices throughout Australia, established in April 1999. Core data variables collected include demographic data, immunological and virological markers, AIDS diagnosis, antiretroviral and prophylactic treatment and cause of death. The first electronic data transfer occurred in September 1999 followed by six monthly data transfers thereafter. All analyses included in this thesis are based on patients recruited to AHOD by March 2004. By March 2004, 2329 patients had been recruited to AHOD from 27 sites throughout Australia. Of these, 352 (15%) patients were recruited from non-metropolitan clinics. The majority of patients were male (94%), and infected with HIV through male homosexual contact (73%). Almost 90% of AHOD patients are antiretroviral treatment experience, and the majority of patients are receiving triple therapy as mandated by standard of care guidelines in Australia. Antiretroviral treatment use has changed in Australia reflecting changes in the availability of new treatment strategies and agents. The crude mortality rate was 1.58 per 100 person years, and of the 105 deaths, more than half died from HIV-unrelated deaths. The prevalence of HBV and HCV in AHOD was 4.8% and 10.9%, respectively. HIV disease progression in the era of highly active antiretroviral treatment (HAART) among AHOD patients is consistent with what has been reported in developed countries. Common factors associated with HIV disease progression were low CD4 cell count, high viral load and prior treatment with mono or double therapy at the time of commencing HAART. This was demonstrated in AHOD in terms of long-term CD4 cell response, the rate of changing combination antiretroviral therapy and factors predicting death. HBV and HCV coinfection is also relatively common in AHOD, similar to other developed country cohorts. Coinfection does not appear to be serious impediments to the treatment of HIV infected patients. However, HIV disease outcome following HAART does appear to be adversely affected by HIV/HCV coinfection but not in terms of HIV/HBV coinfection. Patients attending non-metropolitan sites were found to be similar to those attending metropolitan sites in terms of both immunological response and survival.
APA, Harvard, Vancouver, ISO, and other styles
6

Taylor, Debra Lynn. "Investigation of different antiviral strategies for the treatment of HIV infections." Thesis, Queen Mary, University of London, 1992. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.260877.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Awotedu, Kofoworola Olajire. "Functional changes of the vasculature in HIV/AIDS patients on Haart and Haart Naïve HIV participants." Thesis, Walter Sisulu University, 2013. http://hdl.handle.net/11260/185.

Full text
Abstract:
The present study sought to explore the functional changes that occur in the vasculature of HIV positive participants of African origin in Mthatha district of South africa which might lead to increased risk in their cardiovascular system. Available literature shows that arterial stiffness plays an important role in cardiovascular events such as stroke, vasculitis and myocardial infarction. Measurement of (aortic pulse wave velocity; PWV) provides some of the strongest evidence concerning the prognostic significance of large artery stiffening. This study was aimed at investigating the relationship between anthropometry, age, E-Selectin level, cytokine levels, haemodynamic variables, blood counts and blood lipid profile with pulse wave velocity. Some traditional cardiovascular risk factors such as alcohol, and smoking were also taken into account. This was a cross-sectional study comprising of 169 participants (62 males and 107 females). 63 were HIV negative (group A), 54 HIV positive on treatment (group B), and 52 were HIV positive not on treatment (group C). Pulse wave velocity (PWV) was assessed using the Sphygmocor Vx. Statistically, ANOVA was used for variables with normal distribution and non parametric tests were used for variables with skewed distribution. Notable significant differences were seen in the means of the following variables across all the 3 groups. Conclusion: This study showed that HIV infected patients with or without antiretroviral therapy have increase arterial stiffness which is associated with an increased cardiovascular risk. The sphygmocor is an accurate, non invassive and useful tool in the evaluation of arterial stiffness and its use in clinical practice should be encouraged. PWV and the augmentation index (AIx) are the two major non- iv invasive methods of assessing arterial stiffness. Life style modification should be incorporated into the management of HIV patients so as the continuous monitoring of their haematological and lipid profile.
APA, Harvard, Vancouver, ISO, and other styles
8

Cassidy, Rebecca Jane. "Changing understandings of HIV and AIDS through treatment interactions." Thesis, University of Sussex, 2011. http://sro.sussex.ac.uk/id/eprint/7603/.

Full text
Abstract:
The problem of HIV internationally has many wide ranging impacts on people, communities and countries' development. In the last decade antiretroviral (ARV) treatment has emerged as the major scientific-technical solution, albeit a costly one. Access to ARV treatment is of vital importance across Africa and around the world. Resources for HIV treatment, care and support are transferred globally on a massive scale. However, how such programmes operate ‘on the ground' in different contexts is still unclear. This research contributes to understanding the experience of the people who access such treatment programmes in different contexts. This research focuses on this gap, exploring how treatment programmes are experienced, how the availability of treatment impacts both on people's experience of being HIV+ and how the availability of treatment may also change perceptions of what it means to be HIV+, both individually and at a societal level. This research focuses on the lives and experiences, particularly the treatment experiences, of people living with HIV in peri-urban Gambia. Low prevalence countries such as The Gambia can provide a compelling example of the ways in which meanings and understandings of HIV are created. Here, entering a field of health pluralism and fluid knowledge creation around HIV-infection, came large scale actors providing a high-profile ARV treatment programme through clinic-based medicine, and an effective de-pluralisation of the medical field in relation to HIV, inviting scrutiny of how such knowledge relations and differences are experienced. Although not anticipated at the outset of the research, in parallel the Gambia has become the locus of a major, politically-backed, ‘alternative' AIDS treatment programme. This has thrown the personal and societal meanings of HIV into a new and sensitive context, compelling research attention into how knowledge, status and meanings around HIV are negotiated, and how people make choices amongst different treatment options.
APA, Harvard, Vancouver, ISO, and other styles
9

Mallon, Patrick William Gerard School of Medicine UNSW. "Clinical and molecular aspects of HIV-associated lipodystrophy." Awarded by:University of New South Wales. School of Medicine, 2006. http://handle.unsw.edu.au/1959.4/33048.

Full text
Abstract:
HIV-associated lipodystrophy (HIVLD) syndrome is a condition comprising abnormalities in distribution of body fat and metabolism of lipids and glucose that arises in HIV-infected patients on long-term antiretroviral therapy. This thesis describes clinical research into aspects of the natural history and treatment of HIVLD, as well as molecular research into its pathogenesis centred on subcutaneous adipose tissue. Results demonstrate HIVLD to be a treatment-induced syndrome characterised by initial gains in body fat followed by selective, progressive loss of limb fat. Exposure to thymidineanalogue nucleoside reverse transcriptase inhibitors (tNRTI) induces lipoatrophy through mitochondrial dysfunction of which inhibition of mitochondrial RNA expression, rather than mitochondrial DNA depletion, is an early feature. Mitochondrial dysfunction is associated with decreases in expression of peroxisome proliferatoractivated receptor gamma (PPAR??), an adipocyte transcription factor, which helps explain how tNRTI exposure leads to the loss of adipocyte function. Once established, lipoatrophy is characterised by mitochondrial DNA depletion, although this depletion occurs throughout the mitochondrial genome, suggesting an underlying cause other than inhibition of DNA polymerase gamma. HIVLD is a difficult syndrome to treat. Lipoatrophy is resistant to treatment with rosiglitazone, an agonist of PPAR??, which is ineffective in the setting of ongoing tNRTI therapy and mitochondrial dysfunction. Dyslipidaemia is also difficult to treat as use of pravastatin in the setting of ongoing exposure to protease inhibitors results in only modest declines in fasting cholesterol concentrations. Gains in central fat, such as that seen in patients with buffalo hump, are associated with insulin resistance and diabetes, but only occur in a relatively small percentage of treated patients, suggesting a role for genetic factors in its development. Use of strategies such as avoidance of tNRTI in firstline ART, genetic screening to identify those at risk of toxicities and targeted selection of interventions in subgroups of affected patients, may help prevent this syndrome occurring and better treat those patients in which it has already occurred.
APA, Harvard, Vancouver, ISO, and other styles
10

Hutchinson, Angela Blair. "A health technology assessment of HIV counseling and testing technologies." Diss., Georgia Institute of Technology, 2004. http://hdl.handle.net/1853/8077.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "HIV infections – Treatment – Asia"

1

World Health Organization. Regional Office for South-East Asia. Strategic considerations for scaling up antiretroviral therapy for children living with HIV/AIDS in South-East Asia: Guidelines for programme managers. New Delhi: World Health Organization, Regional Office for South-East Asia, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kane, Brigid M. HIV/AIDS treatment drugs. Edited by Triggle D. J. New York NY: Chelsea House, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kane, Brigid M. HIV/AIDS treatment drugs. New York, NY: Chelsea House, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

HIV: From biology to prevention and treatment. Cold Spring Harbor, N.Y: Cold Spring Harbor Laboratory Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pinsky, Laura. The essential HIV treatment fact book. New York: Pocket Books, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

University, Johns Hopkins, ed. Johns Hopkins HIV guide: Treatment and management of HIV. 2nd ed. Sudbury, Mass: Jones & Bartlett Learning, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Handbook of HIV medicine. 2nd ed. Cape Town: Oxford University Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wilson, Douglas. Handbook of HIV medicine. 2nd ed. Cape Town: Oxford University Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Douglas, Wilson. Handbook of HIV medicine. 2nd ed. Cape Town: Oxford University Press, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Baker, Ronald A. Early care for HIV disease. 2nd ed. San Francisco, CA: San Francisco Aids Foundation, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "HIV infections – Treatment – Asia"

1

Essex, M., and Yichen Lu. "HIV/AIDS: Lessons from a New Disease Pandemic." In Emerging Infections in Asia, 133–42. Boston, MA: Springer US, 2008. http://dx.doi.org/10.1007/978-0-387-75722-3_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Beyrer, Chris, and Henry Stephens. "Transmission of HIV and Other Infections in Southeast Asia." In AIDS in Asia, 317–33. Boston, MA: Springer US, 2004. http://dx.doi.org/10.1007/978-0-306-48536-7_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hirsch, Martin S. "Advances in the Treatment of HIV-1 Infections." In Medical Virology 9, 217–36. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4684-5856-5_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Derouin, Francis, and Jean-Pierre Gangneux. "Treatment and Prophylaxis of Opportunistic Parasitic Intestinal Infections in HIV-Infected Patients." In Textbook-Atlas of Intestinal Infections in AIDS, 427–37. Milano: Springer Milan, 2003. http://dx.doi.org/10.1007/978-88-470-2091-7_27.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jain, Sachin, and Jennifer Adelson-Mitty. "HIV and Other Sexually Transmitted Infections: Testing and Treatment Considerations for Refugees." In Refugee Health Care, 103–13. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0271-2_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Navarrete Gil, Cynthia, Manjula Ramaiah, Andrea Mantsios, Clare Barrington, and Deanna Kerrigan. "Best Practices and Challenges to Sex Worker Community Empowerment and Mobilisation Strategies to Promote Health and Human Rights." In Sex Work, Health, and Human Rights, 189–206. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-64171-9_11.

Full text
Abstract:
AbstractSex workers face a number of health and human rights challenges including heightened risk for HIV infection and suboptimal care and treatment outcomes, institutional and interpersonal violence, labour rights violations, and financial insecurity. In response, sex worker-led groups have been formed and sustained across geographic settings to address these challenges and other needs. Over the last several decades, a growing body of literature has shown that community empowerment approaches among sex workers are associated with significant reductions in HIV and other sexually transmitted infections. Yet legal and policy environments, as well as funding constraints, have often limited the reach, along with the impact and sustainability, of such approaches.In this chapter, we first review the literature on community empowerment and mobilisation strategies as a means to collectively address HIV, violence, and other health and human rights issues among sex workers. We then utilise two case studies, developed by the sex worker-led groups APROASE in Mexico and Ashodaya Samithi in India, to illustrate and contextualise community empowerment processes and challenges, including barriers to scale-up. By integrating the global literature with context-specific case studies, we distil lessons learned and recommendations related to community empowerment approaches among sex workers.
APA, Harvard, Vancouver, ISO, and other styles
7

Chaiwarith, Romanee, Khuanchai Supparatpinyo, and Thira Sirisanthana. "Talaromyces (Penicillium) marneffei infection." In Oxford Textbook of Medicine, edited by Christopher P. Conlon, 1375–78. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198746690.003.0157.

Full text
Abstract:
Talaromyces (formerly Penicillium) marneffei was first isolated from bamboo rats Rhizomys sinensis in Vietnam in 1956. The fungus is endemic in Southeast Asia, north-east India, south China, Hong Kong, and Taiwan. Fewer than 40 cases of infection with T. marneffei were reported before the HIV epidemic. Since then, the incidence of disseminated T. marneffei infection has increased markedly. Talaromyces marneffei infection is very rare in the immunocompetent but one of the most common opportunistic infections in HIV-infected people in Southeast Asia, north-eastern India, southern China, Hong Kong, and Taiwan. Presentation is usually with fever, chills, lymphadenopathy, hepatomegaly, and splenomegaly, with skin lesions—most commonly papules with central necrotic umbilication—in two-thirds of cases. Diagnosis is made by microscopy of bone marrow aspirate or biopsy specimens. Standard treatment, which is usually effective, is with amphotericin B followed by itraconazole.
APA, Harvard, Vancouver, ISO, and other styles
8

"HIV Infection." In Viral Infections and Treatment. Informa Healthcare, 2003. http://dx.doi.org/10.1201/9780203912348.pt3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ogden, Richard. "HIV Protease Inhibitors." In Viral Infections and Treatment. Informa Healthcare, 2003. http://dx.doi.org/10.1201/9780203912348.ch15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

"HIV Protease Inhibitors." In Viral Infections and Treatment, 539–70. CRC Press, 2003. http://dx.doi.org/10.1201/b14823-18.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "HIV infections – Treatment – Asia"

1

Manga, M., H. Farouk, A. Mohammed, U. Hassan, and M. Ibrahim. "P415 Establishment of special treatment clinic for sexually transmitted infections in Gombe Nigeria: realities and prospects." In Abstracts for the STI & HIV World Congress, July 14–17 2021. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/sextrans-2021-sti.440.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Balkus, Jennifer E., Joshua Kimani, Omu Anzala, Emmanuel Kabare, Juma Shafi, and R. Scott Mcclelland. "P2.19 Periodic presumptive treatment for vaginal infections does not impact the incidence of high-risk subtypes of human papilloma virus: a secondary analysis from the preventing vaginal infections trial." In STI and HIV World Congress Abstracts, July 9–12 2017, Rio de Janeiro, Brazil. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/sextrans-2017-053264.195.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fayemiwo, SA, OA Adesina, M. Obaro, O. Awolude, JO Akinyemi, O. Mosuro, MO Kuti, GN Odaibo, and IF Adewole. "P3.55 Pattern of syphilis and hiv co-infections among art treatment naÏve adults in a tertiary institution in ibadan, nigeria." In STI and HIV World Congress Abstracts, July 9–12 2017, Rio de Janeiro, Brazil. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/sextrans-2017-053264.290.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Quilter, Laura, Eve Obondi, Colin Kunzweiler, Duncan Okall, Robert Bailey, Fredrick Otieno, and Susan Graham. "P3.131 An empiric risk score to guide presumptive treatment of asymptomatic anorectal infections in men who have sex with men in kisumu, kenya." In STI and HIV World Congress Abstracts, July 9–12 2017, Rio de Janeiro, Brazil. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/sextrans-2017-053264.366.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Butov, Dmytro, Mykhailo Kuzhko, Mykola Gumeniuk, Oleksiy Denysov, Tetiana Sprynsian, and Tetiana Butova. "Features the effectiveness of the treatment of moxifloxacin in patients with co-infections tuberculosis/HIV and hepatitis B,and/or C." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.484.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Evatt, B. L. "VIRUS INACTIVATION AND COAGULATION FACTOR PREPARATIONS." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644754.

Full text
Abstract:
Nonheat-treated factor concentrates were used for the therapy of congenital and acquired coagulation deficiencies until 1984. These unheated factor crticentrates, which are manufactured from pooled plasma obtained from between 2500 and 25,000 blood or plasma donors, have been epidemiologically implicated in exposure of large numbers of hemophilia patients to several viral infections Including human immunodeficiency virus (HIV), hepatitis B, and non-A non-B hepatitis. Of these, HIV has been fdund to be very heat labile. After the introduction in 1984-85 of heat treatment of concentrates to reduce the risk of! hepatitis to recipients, several studies documented a lack of HIV serconversion in patients treated with clotting-fadtor concentrates. However, subsequent reports described a few hemophilia patients who had seroconverted to HIV! after receiving heat-treated concentrate from unscreened donors. To determine the significance of these seroconvers(ions, an international survey was conducted on 11 hemophilia treatment centers in Europe, Canada, and the United Kingdcpn whose total patient population comprised more than 2300 hemophilia A patients and 400 hemophilia B patients. Only three patients were found who seroconverted beyond a 6-month period after switching to heat-treated material, a(nd no seroconversions have occurred in these centers between November 1985 and February 1987. In addition no cases of seroconversion on donor screened heat-treated concentrate have been reported since its widespread introduction to the hemophilia patients during 1985-1986. Other modes of viral inactivation are currently being tested, and they appeiar to be effective in inactivating HIV and hepatitis B virus. Some of these methods have shown some promise for the inactivation of non-A and non-B hepatitis, but more data are needed for final assessment of these methods.
APA, Harvard, Vancouver, ISO, and other styles
7

Addiego, J. E., P. Bailey, M. Bradley, S. Courter, and M. Lee. "RECOVERY AND SURVIVAL STUDIES OF A NEW FACTOR VIII PRODUCT." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644052.

Full text
Abstract:
Lyophilized protein concentrates are the international treatment of choice to manage bleeding in hemophiliacs. These pooled plasma products, however, expose the recipient of treatment to an increased risk of viral infections. While current manufacturing techniques of these products appear to be effective in eradicating the human immunodeficiency virus (HIV), transmission of other viruses, especially non-A/non-B (NANB) hepatitis, is still a majoor complication of concentrate therapy. Hyland Therapeutics Division Travenol Laboratories, Inc., has developed a new process using the techniques of immunoaffinity chromatography and organic solvent/detergent treatment to prepare a high specific activity product; Antihemophilic Factor (Human), Method M (AHF-M); that may render it free of pathogenic viruses. To determine the recovery and half-life of factor VIII in this product five severe hemophiliacs in a nonbleeding state were given! 50 U/kg of M-AHF and 50 U/kg of a currently licensed factor concentrate (HEMOFILe CT) in a crossover blinded study with a seven day interval between the respective infusions. The table below shows the recovery and half-life results for the five patients studiedThe factor VIII recoveries and half-lifes were similar for both products. No significant adverse clinical reactions were detected in any patient either during or after their infusions. This product appears to produce adequate circulating levels of factor VIII. It also appears to be safe for administration in humans. Further studies are on-going to test the overall efficacy of this product and to confirm that the manufacturing process is effective in eliminating pathogenic viruses
APA, Harvard, Vancouver, ISO, and other styles
8

Levine, P. H. "ACQUIRED IMMUNODEFICIENCY SYNDROME, HUMAN IMMUNODEFICIENCY VIRUS AND HEMOPHILIA." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644752.

Full text
Abstract:
Less than 15 years ago the National Heart, Lung and Blood Institute surveyed physicians in the United States in order to characterize the demographics of hemophilia. The average age of persons with hemophilia in the United States was found to be 11.5 years old. By 10 years later, the life expectancy was predicted to be normal, and indeed the average age of persons with hemophilia in the U.S. is now in the early twenties. Early, intensive and predictably efficacious control of hemorrhage has made this result possible, and the therapeutic product which has allowed such control is commercial clotting factor concentrate.We now know that starting in 1978, and with great frquency during 1982 and 1983, the majority of U.S. hemophiliacs were infected with human immunodeficiency virus (HIV). It is estimated that as of January, 1987, approximately two thirds of the 20,000' persons with hemophilia in the United States have been infected with HIV. Among those with severe factor VIII deficiency, more than 9056 are seropositive. As of 1/5/87, there were 288 cases of AIDS among U.S. hemophiliacs, for an AIDS rate of approximately 2.256 of those with HIV infection. This number included 185 with severe, 32 with moderate and 28 with mild hemophilia A; 12 with severe, 6 with moderate and 1 with mild hemophilia B; 9 with vWD, and 4 others. A disproportionate number were older patients: 55 were ages 1-19; 62 ages 20-29; 85 ages 30-39, and 86 age 40 or older. Although the AIDS attack rate is no longer climbing logarhythmically, new cases are certainly still occurring.A variety of other HIV-related syndromes have emerged. Of great concern is immune thrombocytopenia, which is now relatively common; among a group of 209 carefully followed HIV-positive patients at our center, 31 (1556) are or have been thrombocytopenic. Progressive failure to normally gain height and weight in children with hemophilia has recently been shown by our group to correlate with HIV antibody positivity, and also with decreased T4/T8 ratio, decreased T4 cell count, decreased skin test reactivity, and subsequent development of ARC or AIDS in some such children. Finally, a picture of progressive fall in T4 count associated with recurrent non-specific infections and increased likelihood of positive viral culture, may predict an increased risk of developing AIDS.We know that the immune dysfunction in hemophilia is complex, and not wholly explained by HIV infection. One important factor may be the many foreign proteins contained in commercial clotting factor concentrates, and their ability to stimulate T cells. It is known that latent HIV infection in cultured T4 lymphocytes can be induced to enter the proliferative, viral secretory phase by the addition of soluble foreign antigens to the cell culture. Recent data of Brettler and colleagues, to be presented at this meeting, suggest that the use of highly purified VI!I:C (specific activity >3000 u/mg) in place of the present extremely impure products, may improve the immune dysfunction in hemophilia. This observation offers a new hypothetical approach to the prevention of progressive T4 cell depletion in HIV infected hemophiliacs, and requires immediate and extensive further study.The psychosocial burden of HIV infection is immense. The need for extensive, formal education and support programs is largely unmet in most parts of the world. Such programs are best run out of hemophilia treatment centers in most cases, and must include an active program on prevention of sexual transmission, provision of HIV testing before and during pregnancies, provision for maintenance of confidentiality, etc. Education concerning HIV is like all other forms of education. It requires formal organization, a curriculum, active rather than passive learning in which there is interaction between the teacher and the pupil, time for planned repetition, reinforcement with written materials, and assessment of goals achieved. For all of these reasons it is inappropriate to assume that the physician at the hemophilia center will be able to provide an adequate education program. Adquate paramedical personnel will need to undertake this effort, under the directjon of the physician.
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "HIV infections – Treatment – Asia"

1

Orme, I. M. Early Diagnosis and Treatment of Opportunistic Mycobacterial Infections in HIV-Seropositive AIDS Patients. Fort Belvoir, VA: Defense Technical Information Center, August 1990. http://dx.doi.org/10.21236/ada227796.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Foreit, James R. Postabortion family planning benefits clients and providers. Population Council, 2005. http://dx.doi.org/10.31899/rh16.1006.

Full text
Abstract:
A woman’s fertility can return quickly following an abortion or miscarriage, yet recent data show high levels of unmet need for family planning (FP) among women who have been treated for incomplete abortion. This leaves many women at risk of another unintended pregnancy and in some cases subsequent repeated abortions and abortion-related complications. It is thus vital for programs to provide a comprehensive package of postabortion care (PAC) services that includes medical treatment, FP counseling and services, and other reproductive health services such as evaluation and treatment for sexually transmitted infections, HIV counseling and/or testing, and community support and mobilization. Providing FP services within PAC benefits clients and programs. Facilities that can effectively treat women with incomplete abortions can also provide contraceptive services, including counseling and appropriate methods. As stated in this brief, any provider who can treat incomplete abortion can also provide selected FP methods. Clients, providers, and programs benefit when FP methods are provided to postabortion clients at the time of treatment.
APA, Harvard, Vancouver, ISO, and other styles
3

Patterns and implications of male migration for HIV prevention strategies in Maharashtra, India. Population Council, 2008. http://dx.doi.org/10.31899/hiv16.1003.

Full text
Abstract:
Maharashtra was one of the first states to be affected by HIV in India. Results from the National Family Health Survey (NFHS-3) in 2005–06 indicate that 0.62 percent of men and women aged 15–49 years were infected with HIV, as compared to the national average of 0.28 percent. HIV sentinel surveillance data from sites across Maharashtra indicate that 1.3 percent of pregnant women receiving antenatal care (ANC) and 10.4 percent of patients receiving treatment for sexually transmitted infections in 2005 were infected with HIV. At the same time, Maharashtra ranks first nationally in the proportion of total migrants, and there is a growing consensus among policymakers and program managers that migration could be a major contributor in the spread of HIV in the state. However, empirical evidence to support or refute this conjecture is limited. To address this research gap, the Population Council studied the patterns and motivations related to the migration of male laborers and their linkages with HIV risk. The purpose of the research, as stated in this brief, was to document patterns of male migration and determine whether there was a relationship between migration and HIV prevalence.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'HIV infections – Treatment – Asia' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography